Novo Nordisk (NVO) rallies after Ozempic trial success for kidney problems. The trial included 3,500+ people with Type 2 Diabetes with two-thirds of patients at high risk of chronic kidney disease progress. NVO stopped the Ozempic trial early after positive results for kidney issues. Caroline Woods discusses this news. Tune in to find out more about the stock market today.